2.28
+0.18(+8.57%)
Currency In USD
| Previous Close | 2.1 |
| Open | 2.11 |
| Day High | 2.29 |
| Day Low | 2.07 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.4 |
| Volume | 4.25M |
| Average Volume | 2.64M |
| Market Cap | 376M |
| PE | 4.56 |
| EPS | 0.5 |
| Moving Average 50 Days | 2.24 |
| Moving Average 200 Days | 1.42 |
| Change | 0.18 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $176.74 as of September 07, 2025 at a share price of $2.28. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $344.67 as of September 07, 2025 at a share price of $2.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at Upcoming September Investor Conferences
GlobeNewswire Inc.
Aug 28, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
GlobeNewswire Inc.
Aug 13, 2025 12:00 PM GMT
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 acro
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial re